Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash from Operations: 2009-2025

Historic Cash from Operations for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to -$618,000.

  • Aytu Biopharma's Cash from Operations rose 48.07% to -$618,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year increase of 42.33%. This contributed to the annual value of -$1.9 million for FY2025, which is 39.55% down from last year.
  • Aytu Biopharma's Cash from Operations amounted to -$618,000 in Q3 2025, which was down 122.05% from $2.8 million recorded in Q2 2025.
  • Aytu Biopharma's 5-year Cash from Operations high stood at $19.7 million for Q1 2021, and its period low was -$9.1 million during Q3 2022.
  • For the 3-year period, Aytu Biopharma's Cash from Operations averaged around $229,818, with its median value being -$254,000 (2024).
  • Its Cash from Operations has fluctuated over the past 5 years, first soared by 2,251.85% in 2024, then plummeted by 2,441.34% in 2025.
  • Over the past 5 years, Aytu Biopharma's Cash from Operations (Quarterly) stood at -$8.8 million in 2021, then spiked by 72.18% to -$2.5 million in 2022, then soared by 94.49% to -$135,000 in 2023, then spiked by 2,251.85% to $2.9 million in 2024, then surged by 48.07% to -$618,000 in 2025.
  • Its Cash from Operations was -$618,000 in Q3 2025, compared to $2.8 million in Q2 2025 and -$6.5 million in Q1 2025.